Abcam (OTCMKTS:ABCZY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday. The firm currently has a $18.00 target price on the stock. Zacks Investment Research‘s price target would indicate a potential upside of 9.31% from the stock’s previous close.
According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “
Shares of Abcam (OTCMKTS ABCZY) traded up $0.29 on Friday, reaching $16.47. 1,245 shares of the company’s stock traded hands, compared to its average volume of 843. Abcam has a 1-year low of $9.76 and a 1-year high of $16.15.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.